Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in ...

The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Doctors in New Delhi have achieved two successful live births by treating severe Asherman's Syndrome with umbilical cord-derived stem cells. The pioneering procedure offers new hope to women suffering ...

NorthStrive Fund II LP ("NorthStrive Fund", "we", "our" or "us"), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, is a significant shareholder of Bluejay ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.

Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026U.S. Food and Drug ...

A two-step approach pooled indication-specific response rates, then generated naïve odds ratios via random-effects models, reflecting limited head-to-head evidence across BTK inhibitors. Across ...